A new biological model of moderate inhibition of tumor growth and metastases with prolonged leukopenia on C57Bl/6 mice with the Lewis Lung Carcinoma was designed. The model was created by the injection of cyclophosphamide (dose 83.3mg/kg) on 6th, 12th, 18th days after tumor cells transplantation on animals. Experiment showed that 3-fold cyclo-phosphamide use leads to growth of primary tumor and metastases inhibition. Tumor growth inhibition was 34% on 21st day after cyclophosphamide inject. The number of metastases decreased by 4.7times (p<0,01). Metastatic area reduced. Metastasis frequency made 100%. In addition, the course of cyclophosphamide application caused inhibition of granulocytic and lymphoid hematopoiesis. The reducing the number of segmented neutrophils and lymphocytes was showed on the 3rd day after 1, 2 and 3 injections of cyclophosphamide. The model can be used to study the efficacy of drugs in tumor therapy and in correction of such toxic manifestation of chemotherapy as leukopenia.
experimental model, cyclophosphamide, Lewis lung carcinoma, leukopenia
1. AbramovaEV, DygaiAM, GoldbergVE (1991). Effect of Scutellaria baicalensis Georgi extract on the hemato-poiesis regeneration in C57BL/6 mice with Lewis lung carcinoma under cyclophosphan treatment [Vliyanie ekstrakta shlemnika baykal’skogo na regeneratsiyu krovetvoreniya u myshey linii S57V1/6 s kartsinomoy L’yuisa, poluchavshikh tsiklofosfan]. Eksperimental’naya onkologiya, 13(6), 68-70.
2. AntoneevaII, GeningTP (2007). Neutrophil granu-locytes in the dynamics of ovarian cancer [Neytrofil’nye granulotsity v dinamike progressii raka yaichnikov]. Klinicheskaya laboratornaya diagnostika, (8), 43-46.
3. GlantzS (1998). Biomedical statistics [Mediko-bio-logicheskaya statistika], 459
4. GoldbergED, DygaiAM, ShakhovVP (1992). Hemato-logical methods of tissue culture [Metody kul’tury tkani v gematologii], 264.
5. DygaiAM, ZhdanovVV (2012). Theory of hematopoi-esis regulation [Teoriya regulyatsii krovetvoreniya], 140.
6. ZuevaEP, KozlovAM, GerasimovaGK, AmosovaEN, RazinaTG, GoldbergED (2005). Guidelines for preclinical study of agents with the ability to inhibit the metastasis process and to improve the efficiency of cytostatic ther-apy of malignant tumors [Metodicheskie ukazaniya po doklinicheskomu izucheniyu sredstv, obladayushchikh sposobnost’yu ingibirovat’ protsess metastazirovaniya i povyshat’ effektivnost’ tsitostaticheskoy terapii zlo-kachestvennykh opukholey]. Rukovodstvo po eksperimen-tal’nomu (doklinicheskomu) izucheniyu novykh farmako-logicheskikh veshchestv, 674-682.
7. KormanDB (2006). Basics of anticancer chemother-apy [Osnovy protivoopukholevoy khimioterapii], 512.
8. KokorevOV, CherdyntsevaNV, ZyuzikovaOV (2006). Method of increasing antitumor and antimetastatic activ-ity of cyclophosphamide in experiment: Patent 2270682 of the Russian Federation [Sposob povysheniya protivoopuk-holevoy i antimetastaticheskoy aktivnosti tsiklofosfana v eksperimente: Pat. No 2270682 Ros. Federatsiya].
9. ChuE, DeVitaJr.V (2009). Chemotherapy of tumors [Khimioterapiya zlokachestvennykh novoobrazovaniy], 455.
10. Experimental evaluation of anticancer drugs in the USSR and the United States (1980). [Eksperimen-tal’naya otsenka protivoopukholevykh preparatov v SSSR i SShA],296
11. AbaidLN, MichaJP, RettenmaierMA BrownJV, MendivilAA, LopezKL, GoldsteinBH (2013). A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma. Cancer Chemother. Pharmacol., (May 10).
